Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NAALADL1 (human ileal aminopeptidase, also called N-acetylated alpha-linked acidic dipeptidase like 1 or NAALADase L) is a zinc-dependent metallopeptidase with broad aminopeptidase activity and is highly expressed in the human small intestine, primarily in the ileal brush border membrane[1][4][7]. Unlike the closely related glutamate carboxypeptidase II, NAALADL1 lacks carboxypeptidase and dipeptidyl-peptidase IV type activities and does not act on substrates with both Pro in the P3′ position and Asp or Glu in the P2′ position[1][2][7]. Its main physiological role is associated with the final stages of protein and peptide digestion and absorption in the human digestive process[1][3][4]. It is not currently established as a direct therapeutic target, but its inhibition (e.g., by bestatin) is biochemically characterized[1][3].
Inhibition of aminopeptidase activity (e.g., bestatin inhibits NAALADL1 enzymatic function)[1][3][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human ileal aminopeptidase (NAALADL1).